Emerg Infect Dis by Labarca, J. A. et al.
839Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
Letters
the basis of the following characteristics:
catalase negativity, α-hemolytic gram-positive
cocci forming pairs and tetrads (not chains) in
broth culture; growth in the presence of 40% bile
and 6.5% NaCl and ability to hydrolyze esculin;
pyrrolidony l-aminopeptidase positivity, leucine-
aminopeptidase negativity; and production of
acid from trehalose, sucrose, maltose, and
lactose but not from sorbitol.
Susceptibility testing by the agar dilution
method showed that the isolate was susceptible
to penicillin-G (MIC = 0.12 µg/ml) and vancomycin
(MIC = 0.25 µg/ml). On the basis of this case and
previous reports (1,2), we believe that A. viridans
is a potential pathogen that can cause serious
infections in immunocompromised patients. The
presumed route of infection in this patient was
esophageal ulcers. Clinical microbiologists should
pay close attention to α-hemolytic, catalase-
negative streptococci recovered from sterile body
sites that form tetrads rather than chains on
Gram stain.
Jafar H. Razeq,* Gloria M. Thomas,* and
Daniel Alexander†
*State of Maryland Department of Health and
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Proficiency in Detecting Vancomycin
Resistance in Enterococci among Clinical
Laboratories in Santiago, Chile
To the Editor:  Vancomycin-resistant enterococci
(VRE) can be difficult to detect because of
limitations in the susceptibility testing methods
commonly used in clinical laboratories. Although
VRE have not been reported in Chile, clinical
isolates have been reported in Argentina (1) and
Brazil (2). It is important to detect vancomycin
resistance as early as possible, so infection
control preventive measures can be instituted
when they have their greatest impact. The
microbiology laboratory is the first line of
defense against VRE, as it plays a critical role in
its recognition. In Chile, most laboratories follow
the National Committee for Clinical Laboratory
Standards recommendations for antimicrobial
susceptibility testing and use disk-diffusion
methods (3); however, these methods have
limitations in detecting low levels of resistance to
vancomycin in enterococci.
We evaluated the ability of referral
microbiology laboratories in Chile to detect
vancomycin resistance in five Enteroccocus spp.
isolates with different susceptibility patterns for
vancomycin, penicillin, and ampicillin. Of six
referral laboratories that agreed to participate,
four used the disk-diffusion method to evaluate
antimicrobial susceptibility. Two used an agar
dilution minimum inhibitory concentration (MIC)
method, one as the only susceptibility testing
method and the other in addition to disk diffusion.
The participants correctly evaluated vancomycin
susceptibility in 17 (57%) of 30 isolates.
The accuracy of detecting vancomycin resis-
tance varied according to the level of resistance.
Isolate 1, which had a high level of resistance
(Van A phenotype, MIC 256 µg/ml), was evaluated
correctly in 5 (83%) of 6 laboratories. Isolate 2,
with a lower level of resistance (Van B, MIC
64 µg/ml), was evaluated correctly in 4 (67%) of 6
laboratories. Isolates 3 and 4, both with
intermediate resistance (Van B, MIC 16-32 µg/ml,
and Van C, MIC 8 µg/ml, respectively), were
evaluated correctly by one laboratory each.
Isolate 5 (vancomycin susceptible) was evaluated
correctly by all laboratories. Susceptibility to
penicillin and ampicillin was correctly identified
in 53 (96.4%) of 55 isolates. Although laboratories
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correctly identified E. faecium and E. faecalis to
the species level, most (4 of 5) did not correctly
identify E. gallinarum (three misidentified it as
E. casseliflavus and one as E. faecalis).
The results of this study are consistent with
those of previous studies in the United States
(4,5), South America (6), Spain (7), and
Mexico (8). Although in countries like Chile, disk
diffusion is practical and reliable for most
susceptibility testing, detecting low-level vanco-
mycin resistance in enterocci is difficult without
supplementary testing. In Chile, as in other
countries, strategies should be implemented to
improve detection of these strains, including
improvement of phenotypical and genotypical
methods for VRE detection and species identifica-
tion. Documentation of proficiency in detecting
VRE is important for improving laboratory
performance, detecting clinical isolates, and
accurate and reliable reporting to local, national,
and international surveillance systems.
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Food-Related Illness and Death in the
United States
To the Editor:  Dr. Mead and colleagues should be
commended for attempting to estimate the
prevalence of foodborne disease in the United
States (1). Their study provides more complete
estimates than previous studies in terms of the
number of foodborne pathogens included; for
example, it includes the first realistic estimate of
the number of cases of disease due to Norwalk-
like caliciviruses. However, the publication of
these estimates raises some important issues.
Even though “accurate estimates of disease
burden are the foundation of sound public health
policy” (2), most of these estimates (in particular,
the assumption that unknown agents are
transmitted by food in the same proportion as
known agents) were derived from assumptions
rather than data. Known foodborne agents
clearly cannot account for most gastrointestinal
illnesses (1). However, illnesses from unknown
agents may be as likely to have the transmission
characteristics of rotavirus (1% foodborne) or
Cryptosporidium (10% foodborne) as those of the
Norwalk-like viruses (40% foodborne). Further-
more, it was assumed that detecting outbreaks or
cases of toxin-mediated illnesses (e.g., due to
Bacillus cereus, Staphylococcus aureus, or
Clostridium perfringens) follows the model of
Salmonella. In the authors’ entire list of known
foodborne agents, data are presented for cases
identified both from outbreaks and active
surveillance for only three agents: Salmonella,
Shigella, and Campylobacter. Salmonella is
clearly the most highly characterized, hence the
most attractive as a model. However, the ratios of
the numbers of cases detected through active
surveillance to the numbers of cases detected
through outbreaks range from 10 for Salmonella
to more than 400 for Campylobacter. What if the
ratios for toxin-mediated illnesses were more
